CADPS | Ca++-dependent secretion activator | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
CDH2 | Cadherin 2, type 1, N-cadherin (neuronal) | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CHGA | Chromogranin A (parathyroid secretory protein 1) | Cancer-related genes Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DFNB31 | Deafness, autosomal recessive 31 | Disease related genes Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
DNAJC12 | DnaJ (Hsp40) homolog, subfamily C, member 12 | Predicted intracellular proteins
| | | | | Tissue enhanced |
FDXR | Ferredoxin reductase | Enzymes Mitochondrial proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
GPR123 | G protein-coupled receptor 123 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
HOXA5 | Homeobox A5 | Cancer-related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
INHA | Inhibin, alpha | Predicted secreted proteins
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KLHL4 | Kelch-like family member 4 | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
L1CAM | L1 cell adhesion molecule | CD markers Disease related genes Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MAPK4 | Mitogen-activated protein kinase 4 | Enzymes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
MYO7A | Myosin VIIA | Cytoskeleton related proteins Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
NGB | Neuroglobin | Predicted intracellular proteins
| | | | | Tissue enhanced |
NPTX2 | Neuronal pentraxin II | Predicted secreted proteins
| | | | | Tissue enhanced |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PCSK2 | Proprotein convertase subtilisin/kexin type 2 | Enzymes Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PRPH | Peripherin | Predicted intracellular proteins
| | | | | Tissue enhanced |
RTBDN | Retbindin | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SCG5 | Secretogranin V (7B2 protein) | Predicted secreted proteins
| | | | | Tissue enhanced |
SEPT4 | Septin 4 | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
SERPINA5 | Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 | Cancer-related genes Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SNCG | Synuclein, gamma (breast cancer-specific protein 1) | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
SULT2A1 | Sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
SYT2 | Synaptotagmin II | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TMIE | Transmembrane inner ear | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
TPD52L1 | Tumor protein D52-like 1 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
VAT1L | Vesicle amine transport 1-like | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
ZBED6CL | ZBED6 C-terminal like | Predicted intracellular proteins
| | | | | Tissue enhanced |